NOVARTIS N (NOT MU) stock market data APIs
€123.648
0(0%)
as of September 18, 2026
Try our APIs with
free plan!
NOVARTIS N Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.MU.
Prev. Close
123.648
Open
123.648
High
123.648
Low
123.648
52 wk Range
100.1021-140.82
Market Cap
160 075 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N data using free add-ons & libraries
Get NOVARTIS N Fundamental Data
NOVARTIS N Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N News
New
4 Biotech Stocks to Watch as Potential Takeover Targets
M&A activity in the biotech sector has accelerated sharply in 2026, as large drugmakers increasingly turn to external innovation to strengthen pipelines, expand into new therapeutic areas and gain acc...
Theranostics Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceut...
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Novartis Pharma AG If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹...
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for...
Get NOVARTIS N fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
